Study details
Enrolling now
Phase 1 Trial of Engineered T Cells Targeting KRAS Mutations
AstraZeneca
NCT IDNCT06218914ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
24
Study length
about 20 years
Ages
18+
Locations
18 sites in CA, FL, IL +9
What this study is about
This trial is testing a new treatment called engineered T cells that target KRAS mutations in adults with advanced or metastatic solid tumors. The goal is to determine the safety and how well this treatment works in people.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- 2.Receive NT-112: Autologous, engineered T Cells targeting KRAS G12D
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Part A (Dose Escalation): Evaluate MTD and recommended dose for expansion (RDE)
Body systems
Oncology